INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Rain Oncology Inc. (RAIN) on Behalf of Investors

BENSALEM, Pa.--()--Law Offices of Howard G. Smith announces an investigation on behalf of Rain Oncology Inc. (“Rain” or the “Company”) (NASDAQ: RAIN) investors concerning the Company’s possible violations of federal securities laws.

On May 22, 2023, Rain announced the Phase 3 trial results of its antitumor drug, milademetan, revealing that the trial “did not meet its primary endpoint of progression free survival,” that “the results did not closely mirror prior clinical results” and that the Company would “re-evaluate the path forward for milademetan.”

On this news, Rain’s stock price fell $8.71, or 87.7%, to close at $1.22 per share on May 22, 2023, thereby injuring investors.

If you purchased Rain securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Howard G. Smith, Esquire, of Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020 by telephone at (215) 638-4847, toll-free at (888) 638-4847, or by email to howardsmith@howardsmithlaw.com, or visit our website at www.howardsmithlaw.com.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contacts

Law Offices of Howard G. Smith
Howard G. Smith, Esquire
215-638-4847
888-638-4847
howardsmith@howardsmithlaw.com
www.howardsmithlaw.com

Contacts

Law Offices of Howard G. Smith
Howard G. Smith, Esquire
215-638-4847
888-638-4847
howardsmith@howardsmithlaw.com
www.howardsmithlaw.com